Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
SUPve68YUprbAXBu